Infrastructure name

    StemBANCC (FP7-IMI-Seventh Framework Programme/Innovative Medicines Initiative)


    Key contact

    Contact phone number

    Contact email

    Project/infrastructure description

    Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC)

    Date funding committed


    Date infrastructure operational

    Total capital cost (Euros)

    € 26,000,000

    Does the 'Total Capital Cost' include other associated costs?

    Current infrastructure status

    Is this entry applicable to another section of this questionnaire?

    Further information available at:

    The aim of the STEMBANCC project is to generate and characterise 1 500 high quality human induced pluripotent stem (iPS) cell lines that can be used by researchers to study a range of diseases, including diabetes and dementia, and test for drug efficacy and safety. The cell lines will help to improve and speed up the drug development process, and ensure that patients benefit from more effective and safer drugs. Stem cells, iPSC, diabetes, neurological, toxicology, assay development, biobank

Types: Capital Infrastructure
Member States: European Commission
Diseases: N/A
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF